Company intelligence / Profile preview

Zhejiang East Asia Pharmaceutical

Taizhou, Zhejiang, Chinaeapharm.cn ↗

Ownership: Private
Employees: ~1150
Development stage: Commercial

Overview

Zhejiang East Asia Pharmaceutical is a leading Chinese pharmaceutical company focused on the development and manufacture of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company has multiple products approved in China and internationally. It conducts bioequivalence studies for generic drugs such as trimebutine maleate tablets and epalrestat tablets. Several products have passed cGMP certification as well as EU EDQM and Japan PMDA certifications. The company’s clinical results are primarily related to bioequivalence trials for generics.

Therapeutic areas: EndocrinologyGastroenterologyCardiovascularNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Zhejiang East Asia Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang East Asia Pharmaceutical.

Explore the full profile